You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Moodys
Dow
Mallinckrodt
Johnson and Johnson
Harvard Business School
Colorcon

Last Updated: July 10, 2020

DrugPatentWatch Database Preview

Mylan Pharms Inc Company Profile


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

What is the competitive landscape for MYLAN PHARMS INC, and what generic and branded alternatives to MYLAN PHARMS INC drugs are available?

MYLAN PHARMS INC has one hundred and sixteen approved drugs.

There are twenty-one tentative approvals on MYLAN PHARMS INC drugs.

Summary for Mylan Pharms Inc
US Patents:0
Tradenames:103
Ingredients:101
NDAs:116

Drugs and US Patents for Mylan Pharms Inc

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Mylan Pharms Inc MALATHION malathion LOTION;TOPICAL 078743-001 Mar 6, 2009 DISCN No No   Start Trial   Start Trial
Mylan Pharms Inc BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE benazepril hydrochloride; hydrochlorothiazide TABLET;ORAL 076612-002 Feb 11, 2004 DISCN No No   Start Trial   Start Trial
Mylan Pharms Inc ALPRAZOLAM alprazolam TABLET;ORAL 074046-001 Oct 19, 1993 DISCN No No   Start Trial   Start Trial
Mylan Pharms Inc PAROXETINE HYDROCHLORIDE paroxetine hydrochloride TABLET;ORAL 075716-001 Mar 8, 2004 DISCN No No   Start Trial   Start Trial
Mylan Pharms Inc SERTRALINE HYDROCHLORIDE sertraline hydrochloride TABLET;ORAL 076540-001 Mar 20, 2007 DISCN No No   Start Trial   Start Trial
Mylan Pharms Inc METOPROLOL SUCCINATE metoprolol succinate TABLET, EXTENDED RELEASE;ORAL 202033-003 Dec 15, 2011 AB RX No No   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Mylan Pharms Inc

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Mylan Pharms Inc AVITA tretinoin CREAM;TOPICAL 020404-003 Jan 14, 1997 4,971,800   Start Trial
Mylan Pharms Inc MAXZIDE hydrochlorothiazide; triamterene TABLET;ORAL 019129-001 Oct 22, 1984 4,444,769   Start Trial
Mylan Pharms Inc MAXZIDE hydrochlorothiazide; triamterene TABLET;ORAL 019129-001 Oct 22, 1984 4,105,783   Start Trial
Mylan Pharms Inc MAXZIDE-25 hydrochlorothiazide; triamterene TABLET;ORAL 019129-003 May 13, 1988 4,444,769   Start Trial
Mylan Pharms Inc AVITA tretinoin CREAM;TOPICAL 020404-003 Jan 14, 1997 5,045,317   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Boehringer Ingelheim
Dow
McKinsey
Express Scripts
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.